Cellnovo, a company working towards the development of new insulin delivery technologies, recently received CE Mark approval for its mobile diabetes management system, the first of its kind that the world has seen. The approval is an important milestone for Cellnovo in offering new, flexible technologies that aid diabetics in managing their disease.

“This is Cellnovo’s first step in a journey to bring this mobile diabetes management system to the world,” said William McKeon, Chief Executive Officer at Cellnovo.

The management system, also called Cellnovo, utilized mobile, wireless technology to aid diabetics in the management of their disease. The system is composed of an insulin patch pump, a touch-screen handset equipped with a blood glucose monitor, and an extendable applications set.

“Cellnovo has created the first insulin pump that brings innovation and combines form with function, essential qualities in a device that patients have to interact with 24/7,” said Dr. Pratik Choudhary, a Clinical Lecturer in Diabetes at King’s College London.

The patch pump developed by Cellnovo is the smallest and most precise one yet. The touch screen interface that the system uses will also be familiar and easy to navigate for anyone who has used a handheld mobile device such as an iPhone.

“Cellnovo has combined advanced mobile and medical technology which may create a paradigm shift in diabetes care,” according to Irl B. Hirsch, Professor of Medicine at the University of Washington in Seattle. “For the multitude of patients who could benefit from pump therapy, Cellnovo could be a game-changer.”

Perhaps the most innovative feature of Cellnovo’s diabetes management system is its ability to receive and transmit data wirelessly and in real-time to a portal that both patients and physicians have access to. The automated transmission of blood glucose data simplifies the process of keeping track of such information for patients, removing the need for diabetics to keep track of every measurement. It also ensures that the data is collected quickly, accurately, and consistently, allowing constant and efficient monitoring of the disease by health care professionals. This new capability could redefine the models that physicians use to treat diabetics, according to Dr. Mark Evans, a lecturer and Honorary Consultant with the Institute of Metabolic Science at the University of Cambridge.

“The ability to see real-time data of patients who may be hundreds of miles away provides the opportunity to redefine our care model,” said Dr. Evans.

Dr. David Kerr, a Consultant Physician and Diabetologist at Bournemouth Diabetes and Endocrine Centre, was also optimistic about the role that Cellnovo could play in revolutionizing diabetes care. “Cellnovo has the potential to break new ground in bringing the first mobile diabetes management system to market. It is clear that new technologies for diabetes care, such as Cellnovo’s mobile health solution, are going to forever change the way we practice medicine and more effectively manage diabetes long into the future.”

Cellnovo previously announced that it would be partnering with LifeScan, a Johnson & Johnson company based in California, to utilize LifeScan’s blood glucose monitoring technology with the Cellnovo mobile management system.

“We wanted superb blood glucose monitoring technology inside our mobile handset and LifeScan is a market leader,” said William McKeon, Chief Executive Officer of Cellnovo. “Through our partnership with LifeScan, our combined technologies will advance care through connectivity.”

Cellnovo is a mobile health technology company based in the U.K. Cellnovo’s goal is to utilize mobile technology to allow diabetics greater freedom and simplifying the process of insulin administration and glucose monitoring.